Skip to main content
Terug
VTRLY logo

Vitrolife AB (publ)

Datakwaliteit: 100%
VTRLY
OTC Healthcare Medical - Devices
€ 11,00
€ 0,00 (0,00%)
Marktkapitalisatie: 1,49B
Dagbereik
€ 11,00 € 11,00
52-Weeksbereik
€ 9,50 € 18,55
Volume
130
50D / 200D Gem.
€ 12,38 / € 14,80
Vorige Slotkoers
€ 11,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -0,3 0,4
P/B 0,2 2,9
ROE % -46,6 3,7
Net Margin % -145,7 3,8
Rev Growth 5Y % 19,6 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue grew 19,61% annually over 5 years — strong growth
Earnings declined -1077,00% over the past year
Debt/Equity of 0,20 — conservative balance sheet
Generating 343,10M in free cash flow
PEG of 0,00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 24,29%

Groei

Revenue Growth (5Y)
19,61%
Revenue (1Y)-4,68%
Earnings (1Y)-1077,00%
FCF Growth (3Y)-26,67%

Kwaliteit

Return on Equity
-46,55%
ROIC4,57%
Net Margin-145,70%
Op. Margin16,83%

Veiligheid

Debt / Equity
0,20
Current Ratio3,40
Interest Coverage12,08

Waardering

P/E Ratio
-0,30
P/B Ratio0,19
EV/EBITDA3,95
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4,68% Revenue Growth (3Y) -1,03%
Earnings Growth (1Y) -1077,00% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19,61% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,44B Net Income (TTM) -5,01B
ROE -46,55% ROA -45,06%
Gross Margin 58,05% Operating Margin 16,83%
Net Margin -145,70% Free Cash Flow (TTM) 343,10M
ROIC 4,57% FCF Growth (3Y) -26,67%
Safety
Debt / Equity 0,20 Current Ratio 3,40
Interest Coverage 12,08 Dividend Yield 0,01%
Valuation
P/E Ratio -0,30 P/B Ratio 0,19
P/S Ratio 0,43 PEG Ratio 0,00
EV/EBITDA 3,95 Dividend Yield 0,01%
Market Cap 1,49B Enterprise Value 2,29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,44B 3,61B 3,51B 3,23B 1,68B
Net Income -5,01B 513,00M -3,85B 394,00M 341,00M
EPS (Diluted) -34,79 3,78 -28,44 2,91 2,97
Gross Profit 2,00B 2,14B 1,98B 1,78B 1,05B
Operating Income 579,03M 783,00M -3,59B 654,00M 435,38M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11,12B 17,45B 16,33B 20,55B 19,43B
Total Liabilities 3,23B 3,81B 3,61B 3,81B 4,09B
Shareholders' Equity 7,89B 13,64B 12,72B 16,74B 15,32B
Total Debt 1,61B 2,09B 2,09B 2,23B 2,48B
Cash & Equivalents 809,00M 1,14B 861,00M 578,00M 630,09M
Current Assets 2,09B 2,36B 1,91B 1,57B 1,41B
Current Liabilities 615,00M 705,00M 557,00M 621,00M 954,33M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#412 of 820
42

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026